The FDA has delayed the approval of MDMA-assisted therapy for PTSD, citing the need for additional safety and efficacy data. Is this the end for...

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

The Food and Drug Administration (FDA), as many are aware, is the leading entity for the regulation and safety testing for foods and pharmaceuticals...

After some back-breaking work tearing apart a deck, columnist John Swart takes a look at the differing opinions on the rapidly growing trend of...

After some back-breaking work tearing apart a deck, columnist John Swart takes a look at the differing opinions on the rapidly growing trend of...

CellProthera, a regenerative cell therapy developer specialising in ischemic diseases, announced alignment with regulators on a planned pivotal phase...

Industry-Leading Research Provides 360-Degree View of Hydrogen as a Marine Fuel and Wind-Assisted Propulsion A 360-degree analysis of hydrogen as...